This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Alimera Sciences Balans Gezondheid
Financiële gezondheid criteriumcontroles 3/6
Alimera Sciences has a total shareholder equity of $38.8M and total debt of $69.7M, which brings its debt-to-equity ratio to 179.8%. Its total assets and total liabilities are $150.4M and $111.6M respectively. Alimera Sciences's EBIT is $2.4M making its interest coverage ratio 0.2. It has cash and short-term investments of $10.8M.
Belangrijke informatie
179.8%
Verhouding schuld/eigen vermogen
US$69.73m
Schuld
| Rente dekkingsratio | 0.2x |
| Contant | US$10.83m |
| Aandelen | US$38.79m |
| Totaal verplichtingen | US$111.59m |
| Totaal activa | US$150.38m |
Recente financiële gezondheidsupdates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: ASZ1's short term assets ($55.4M) exceed its short term liabilities ($19.8M).
Langlopende schulden: ASZ1's short term assets ($55.4M) do not cover its long term liabilities ($91.8M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: ASZ1's net debt to equity ratio (151.9%) is considered high.
Schuld verminderen: ASZ1 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: ASZ1 has sufficient cash runway for more than a year based on its current free cash flow.
Voorspelling contante baan: ASZ1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 47.6% each year